# 42 U.S.C. 1320f-1 Selection of negotiation-eligible drugs as selected drugs

42 U.S.C. 1320f-1 Selection of negotiation-eligible drugs as selected drugs, “Selection of negotiation-eligible drugs as selected drugs”, is a U.S. Code section of [Part E—Price Negotiation Program to Lower Prices for Certain High-Priced Single Source Drugs](https://ontology.bommaritollc.com/id/01a0f07c-d374-7601-95ff-719446e7acd3); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d>

Within: [Title 42—The Public Health and Welfare](https://ontology.bommaritollc.com/id/01a0f07c-d251-723d-b1d9-a44e9ccd25c7) › [Chapter 7—Social Security](https://ontology.bommaritollc.com/id/01a0f07c-d363-76d2-9057-fafa67260f8f) › [Subchapter XI—General Provisions, Peer Review, and Administrative Simplification](https://ontology.bommaritollc.com/id/01a0f07c-d370-70d9-96bf-bed2d7781bae) › [Part E—Price Negotiation Program to Lower Prices for Certain High-Priced Single Source Drugs](https://ontology.bommaritollc.com/id/01a0f07c-d374-7601-95ff-719446e7acd3)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 42 U.S.C. 1320f-1](https://ontology.bommaritollc.com/id/01a0f07c-e07d-77db-b182-99a15119dde3)
- `eli:cites`:
  - [15 U.S.C. 78l Registration requirements for securities](https://ontology.bommaritollc.com/id/01a0ee1d-4cef-76bf-a87f-f7d52ea7c640)
  - [15 U.S.C. 78m Periodical and other reports](https://ontology.bommaritollc.com/id/01a0ee1d-4cf6-7650-9e2d-031e1d84e54b)
  - [15 U.S.C. 78o Registration and regulation of brokers and dealers](https://ontology.bommaritollc.com/id/01a0ee1d-4d07-771d-9830-83cd1aec0ebb)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 360bb Designation of drugs for rare diseases or conditions](https://ontology.bommaritollc.com/id/01a0f06c-cd1e-70fc-bda3-7fe5eb2d38cf)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
  - [42 U.S.C. 1320f-2 Manufacturer agreements](https://ontology.bommaritollc.com/id/01a0f07c-e07d-77db-b182-99a3e31d0c5d)
  - [42 U.S.C. 1320f-3 Negotiation and renegotiation process](https://ontology.bommaritollc.com/id/01a0f07c-e07e-750e-8424-d81ef2c9ff35)
  - [42 U.S.C. 1320f-4 Publication of maximum fair prices](https://ontology.bommaritollc.com/id/01a0f07c-e07f-772e-a03f-4a5ee3170754)
  - [42 U.S.C. 1395t Federal Supplementary Medical Insurance Trust Fund](https://ontology.bommaritollc.com/id/01a0f07c-e0ca-7238-b1f6-ca4d4622633f)
  - [42 U.S.C. 1395w-3a Use of average sales price payment methodology](https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac)
  - [42 U.S.C. 1395w-102 Prescription drug benefits](https://ontology.bommaritollc.com/id/01a0f07c-e11a-725c-9f6d-0bce71771fe1)
  - [42 U.S.C. 1395w-114a Medicare coverage gap discount program](https://ontology.bommaritollc.com/id/01a0f07c-e121-7069-923d-0ae721626714)
  - [42 U.S.C. 1395w-114c Manufacturer discount program](https://ontology.bommaritollc.com/id/01a0f07c-e123-705e-a465-47a965d55121)
  - [42 U.S.C. 1395w-116 Medicare Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund](https://ontology.bommaritollc.com/id/01a0f07c-e126-7613-b822-64867436b720)
  - [42 U.S.C. 1396r-8 Payment for covered outpatient drugs](https://ontology.bommaritollc.com/id/01a0f07c-e17e-7431-ad8e-b86bb6c0b818)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title42/USCODE-2024-title42-chap7-subchapXI-partE-sec1320f-1](https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e52e1fe3d66)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f07d-0612-72c4-88b7-3b51f852eaba)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-52fe-73be-a20e-533b920f0a83)
  - [evidence from https://www.govinfo.gov/link/uscode/42/1320f-1?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f16-17dd-7605-8b2a-d5b6d74aa51f)
- `schema:isPartOf`: [Part E—Price Negotiation Program to Lower Prices for Certain High-Priced Single Source Drugs](https://ontology.bommaritollc.com/id/01a0f07c-d374-7601-95ff-719446e7acd3)
- `schema:legislationIdentifier`: 42 U.S.C. 1320f-1
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Selection of negotiation-eligible drugs as selected drugs
- `schema:url`: [https://www.govinfo.gov/link/uscode/42/1320f-1?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/42/1320f-1?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 42 U.S.C. 1320f-1 Selection of negotiation-eligible drugs as selected drugs

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/42/1320f-1?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title42/USCODE-2024-title42-chap7-subchapXI-partE-sec1320f-1) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (14; `eli:cites`):
  - [42 U.S.C. 1320f Establishment of program](https://ontology.bommaritollc.com/id/01a0f07c-e07b-7379-87a5-77617d9e2ec8)
  - [42 U.S.C. 1320f-2 Manufacturer agreements](https://ontology.bommaritollc.com/id/01a0f07c-e07d-77db-b182-99a3e31d0c5d)
  - [42 U.S.C. 1320f-3 Negotiation and renegotiation process](https://ontology.bommaritollc.com/id/01a0f07c-e07e-750e-8424-d81ef2c9ff35)
  - [42 U.S.C. 1320f-5 Administrative duties and compliance monitoring](https://ontology.bommaritollc.com/id/01a0f07c-e080-7172-9a8d-670b7a61671b)
  - [42 U.S.C. 1320f-6 Civil monetary penalties](https://ontology.bommaritollc.com/id/01a0f07c-e081-7356-bcaf-5071829a267b)
  - [42 U.S.C. 1320f-7 Limitation on administrative and judicial review](https://ontology.bommaritollc.com/id/01a0f07c-e082-718b-a376-5b225c638b9b)
  - [42 U.S.C. 1395l Payment of benefits](https://ontology.bommaritollc.com/id/01a0f07c-e0c2-7095-ad6d-d895e786c4df)
  - [42 U.S.C. 1395w-102 Prescription drug benefits](https://ontology.bommaritollc.com/id/01a0f07c-e11a-725c-9f6d-0bce71771fe1)
  - [42 U.S.C. 1395w-104 Beneficiary protections for qualified prescription drug coverage](https://ontology.bommaritollc.com/id/01a0f07c-e11c-7007-aa18-58f8b738b30f)
  - [42 U.S.C. 1395w-114b Manufacturer rebate for certain drugs with prices increasing faster than inflation](https://ontology.bommaritollc.com/id/01a0f07c-e122-7770-a968-a78478520c77)
  - [42 U.S.C. 1395w-114c Manufacturer discount program](https://ontology.bommaritollc.com/id/01a0f07c-e123-705e-a465-47a965d55121)
  - [42 U.S.C. 1395w-22 Benefits and beneficiary protections](https://ontology.bommaritollc.com/id/01a0f07c-e10d-705e-9fd0-86615bcafbc1)
  - [42 U.S.C. 1395w-3a Use of average sales price payment methodology](https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac)
  - [42 U.S.C. 1396r-8 Payment for covered outpatient drugs](https://ontology.bommaritollc.com/id/01a0f07c-e17e-7431-ad8e-b86bb6c0b818)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 117-169](https://ontology.bommaritollc.com/id/01a0edf4-a81c-717e-8db0-57c66c114e6c)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d)
Cite as: 42 U.S.C. 1320f-1 Selection of negotiation-eligible drugs as selected drugs. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
